0 have signed. Let’s get to 5,000!

CALL TO ACTION: Augmentation therapy for alpha-1 patients needs to be added as a category on the Canadian Blood Services Plasma Protein Products Formulary.
We, the undersigned, expect that augmentation therapy for Canadian alpha-1 patients be added as a category on the Canadian Blood Services (CBS) Plasma Protein Products Formulary to ensure this plasma protein replacement therapy is managed and distributed by the nation’s blood operator (outside of Quebec), ensuring equitable access for all severely affected alpha-1 antitrypsin deficient patients.
Augmentation therapy for alpha-1 antitrypsin deficiency is a biological drug manufactured from human plasma, used in the practice of transfusion medicine, and it is not carried in the health system already. The only province that provides unrestricted access to augmentation therapy as a regular benefit on a provincial formulary is British Columbia.
Replacement therapy, for severe alpha-1 antitrypsin deficiency, is a plasma-derived therapy and it is in the mandate of CBS as per the Memorandum of Understanding between the provinces and territories and CBS to ensure access and availability of blood and blood related products to Canadian patients (outside of Quebec).
We, the undersigned, join the following organizations in endorsing the inclusion of augmentation therapy on the Canadian Blood Services Plasma Protein Products Formulary:
·       The Canadian Thoracic Society
·       The Canadian Lung Association
·       The Alpha-1 Canadian Registry
·       Canadian Vascular Access Association (CVAA)
·       The National Rare Blood Disorders Organization (NRBDO)
·       The Canadian Network for Respiratory Care (CNRC)
·       The Canadian Society of Respiratory Therapists (CSRT)
·       The Plasma Protein Therapeutics Association (PPTA) 
·       Canadian Association of Genetic Counsellors (CAGC)
·       The Family Physician Airways Group of Canada (FPAGC)
·       AlphaNet Canada
·       Alpha-1 Foundation
Alpha-1 Canada is petitioning the provincial and territorial governments to urgently proceed with listing augmentation therapy with Canadian Blood Services, ensuring no more Canadians needlessly die prematurely from alpha-1 antitrypsin deficiency.